Institut Pasteur De Lille

ILiAD and hVIVO Partner for Phase 3 Human Challenge Trial of BPZE1 Pertussis Vaccine

4 months ago

• ILiAD Biotechnologies and hVIVO have signed a Letter of Intent to conduct a pivotal Phase 3 human challenge trial for ILiAD's BPZE1 pertussis vaccine. • The trial, anticipated to begin in H2 2025, will evaluate BPZE1, a next-generation intranasal vaccine, against whooping cough caused by *Bordetella pertussis*. • This landmark study marks the first Phase 3 trial using a human challenge model for pertussis, addressing the unpredictability of natural outbreaks. • BPZE1 aims to provide comprehensive and durable protection against *B. pertussis* infection and disease, potentially preventing transmission, including to infants.